Confluence Wealth Services Inc. Has $269,000 Stock Holdings in Lam Research Co. (NASDAQ:LRCX)

Confluence Wealth Services Inc. increased its stake in shares of Lam Research Co. (NASDAQ:LRCX) by 1,103.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 3,730 shares of the semiconductor company’s stock after acquiring an additional 3,420 shares during the period. Confluence Wealth Services Inc.’s holdings in Lam Research were worth $269,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Atwood & Palmer Inc. bought a new stake in shares of Lam Research during the 4th quarter worth approximately $27,000. West Oak Capital LLC raised its position in Lam Research by 50.9% during the fourth quarter. West Oak Capital LLC now owns 400 shares of the semiconductor company’s stock worth $29,000 after acquiring an additional 135 shares in the last quarter. Country Trust Bank lifted its stake in Lam Research by 900.0% in the fourth quarter. Country Trust Bank now owns 400 shares of the semiconductor company’s stock valued at $29,000 after acquiring an additional 360 shares during the last quarter. Finley Financial LLC bought a new position in shares of Lam Research in the 4th quarter valued at about $30,000. Finally, Stephens Consulting LLC increased its stake in shares of Lam Research by 900.0% during the 4th quarter. Stephens Consulting LLC now owns 430 shares of the semiconductor company’s stock worth $31,000 after purchasing an additional 387 shares during the last quarter. 84.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LRCX. Sanford C. Bernstein upgraded shares of Lam Research from a “market perform” rating to an “outperform” rating and raised their target price for the company from $85.00 to $91.00 in a research note on Thursday, January 30th. BNP Paribas raised Lam Research to a “hold” rating in a research report on Thursday, October 24th. Mizuho decreased their target price on Lam Research from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, January 10th. Barclays cut their price target on Lam Research from $90.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Finally, The Goldman Sachs Group decreased their price objective on shares of Lam Research from $96.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Seven research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Lam Research presently has a consensus rating of “Moderate Buy” and an average target price of $95.72.

Lam Research Price Performance

Lam Research stock opened at $81.94 on Thursday. The stock’s fifty day moving average price is $76.32 and its two-hundred day moving average price is $78.33. The firm has a market cap of $105.18 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 1.34 and a beta of 1.46. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.54 and a quick ratio of 1.73. Lam Research Co. has a one year low of $68.87 and a one year high of $113.00.

Lam Research (NASDAQ:LRCX) last posted its quarterly earnings results on Wednesday, January 29th. The semiconductor company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.04. Lam Research had a return on equity of 51.86% and a net margin of 26.49%. As a group, research analysts expect that Lam Research Co. will post 3.69 EPS for the current fiscal year.

Lam Research Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.